You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復宏漢霖-B(2696.HK)超額認購2.89倍,今日正式上市
格隆匯 09-25 09:30

格隆匯9月25日| 復宏漢霖-B(2696.HK)今日正式登錄港交所主板上市,發行價每股49.60港元,初始市值267億港元。

其中,香港公開發售項下提呈發售的H股獲超額認購,認購合共2513.53萬股香港發售股份,相當於香港公開發售項下初步可供認購的646.96萬股香港發售股份總數約3.89倍。

國際發售獲超額認購。國際發售項下發售股份最終數目為58,225,800股發售股份,相當於全球發售項下初步可供認購的發售股份約90%。

據悉,復宏漢霖是一家中國領先的生物醫藥公司,旨在為全球患者提供質高價優的創新生物藥,產品覆蓋腫瘤、自身免疫性疾病等領域。

截至目前,復宏漢霖已有1個產品成功上市,2個產品獲得新藥上市申請受理,14個產品、6個聯合治療方案在全球範圍內開展20多項臨牀試驗。公司首款重磅產品漢利康®(利妥昔單抗注射液)作為中國首個生物類似藥於2019年2月獲國家藥監局新藥上市註冊批准,5月正式開始銷售,公司赴港上市前已產生營收。

HLX03(阿達木單抗注射液)與HLX02(注射用曲妥珠單抗)已獲國家藥監局新藥上市申請受理,現已納入優先審評程序。此外,公司已陸續就HLX10與自有產品HLX04(貝伐珠單抗生物類似藥)、HLX07(抗EGFR單抗)等單抗以及化療聯用開展多項腫瘤免疫聯合療法,在全球範圍內開展多個臨牀研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account